L

L&C Bio Co Ltd
KOSDAQ:290650

Watchlist Manager
L&C Bio Co Ltd
KOSDAQ:290650
Watchlist
Price: 62 100 KRW -0.48% Market Closed
Market Cap: 1.5T KRW

L&C Bio Co Ltd
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

L&C Bio Co Ltd
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
L
L&C Bio Co Ltd
KOSDAQ:290650
Revenue
â‚©76B
CAGR 3-Years
15%
CAGR 5-Years
20%
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Revenue
â‚©3.9T
CAGR 3-Years
18%
CAGR 5-Years
18%
CAGR 10-Years
22%
P
PharmaResearch Co Ltd
KOSDAQ:214450
Revenue
â‚©449.8B
CAGR 3-Years
37%
CAGR 5-Years
37%
CAGR 10-Years
30%
Alteogen Inc
KOSDAQ:196170
Revenue
â‚©158.1B
CAGR 3-Years
64%
CAGR 5-Years
29%
CAGR 10-Years
39%
A
ABL Bio Inc
KOSDAQ:298380
Revenue
â‚©94.9B
CAGR 3-Years
109%
CAGR 5-Years
96%
CAGR 10-Years
N/A
D
DND PharmaTech Inc
KOSDAQ:347850
Revenue
â‚©11.4B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

L&C Bio Co Ltd
Glance View

Market Cap
1.5T KRW
Industry
Biotechnology

L&C BIO Co., Ltd. develops soft tissue, allografts, and medical devices. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-11-01. The firm mainly manufactures and sells human tissue transplant materials used for tissue repair and filler. The firm also produces and sells human tissue-based medical devices and Cosmeceuticals. Its products are used in vascular surgeries, plastic surgeries, general surgeries and others.

Intrinsic Value
20 028.44 KRW
Overvaluation 68%
Intrinsic Value
Price
L

See Also

What is L&C Bio Co Ltd's Revenue?
Revenue
76B KRW

Based on the financial report for Jun 30, 2025, L&C Bio Co Ltd's Revenue amounts to 76B KRW.

What is L&C Bio Co Ltd's Revenue growth rate?
Revenue CAGR 5Y
20%

Over the last year, the Revenue growth was 5%. The average annual Revenue growth rates for L&C Bio Co Ltd have been 15% over the past three years , 20% over the past five years .

Back to Top